Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) was the recipient of a large decline in short interest in August. As of August 31st, there was short interest totalling 3,150,000 shares, a decline of 26.4% from the August 15th total of 4,280,000 shares. Based on an average daily trading volume, of 2,710,000 shares, the days-to-cover ratio is currently 1.2 days.
Allena Pharmaceuticals stock opened at $0.91 on Tuesday. Allena Pharmaceuticals has a fifty-two week low of $0.75 and a fifty-two week high of $2.78. The firm has a market capitalization of $72.53 million, a PE ratio of -0.99 and a beta of 2.17. The company’s 50-day moving average is $0.95 and its 200-day moving average is $1.17. The company has a debt-to-equity ratio of 0.81, a current ratio of 3.63 and a quick ratio of 3.63.
Allena Pharmaceuticals (NASDAQ:ALNA) last announced its quarterly earnings results on Monday, August 9th. The company reported ($0.24) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.21) by ($0.03). As a group, analysts expect that Allena Pharmaceuticals will post -0.81 EPS for the current year.
Several brokerages have commented on ALNA. Zacks Investment Research cut shares of Allena Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, August 9th. B. Riley lowered their price objective on shares of Allena Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating on the stock in a research note on Wednesday, August 18th. Finally, HC Wainwright boosted their price objective on shares of Allena Pharmaceuticals from $10.00 to $11.00 and gave the stock a “buy” rating in a research note on Wednesday, August 11th.
About Allena Pharmaceuticals
Allena Pharmaceuticals, Inc engages in the development, discovery and commercialization of oral enzyme therapeutics to treat patients with kidney disorders. Its product pipeline includes reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria in adults and ALLN-346, which is used for patients with hyperuricemia and moderate to severe chronic kidney disease.
Read More: Earnings Reports
Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.